Personalized medicine may let some diabetes patients ditch mealtime insulin
NCT ID NCT06148376
First seen Mar 18, 2026 · Last updated May 15, 2026 · Updated 11 times
Summary
This study tested a personalized approach to see if some people with type 2 diabetes who take multiple daily insulin injections could safely stop their mealtime insulin. Researchers used blood tests (C-peptide and GAD antibodies) to guide treatment decisions. 239 participants wore continuous glucose monitors and were followed for 6 months. The goal was to simplify treatment without harming blood sugar control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centres Atenció Primària Lleida, Alt Pirineu i Aran
Lleida, Spain
-
Hospital Universitari Arnau de Vilanova
Lleida, 25198, Spain
Conditions
Explore the condition pages connected to this study.